Hanna Zurl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hanna Zurl has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Putnam Cole
Brigham and Women’s Hospital
7 shared publications - Filippo Dagnino
Department of Urology Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Urology, Humanitas Research Hospital - IRCCS, Milan, Italy; Department of Biomedical Sciences, Humanitas University - Milan, Italy
7 shared publications - Quoc-Dien Trinh
Department of Urology, University of Pittsburgh, Pittsburgh, PA
7 shared publications - Zhiyu Qian
Department of Urology, Harvard Medical School Brigham and Women's Hospital Boston Massachusetts USA
7 shared publications - Daniel Stelzl
Department of Urology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
6 shared publications - Klara Pohl
Department of Urology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
5 shared publications
Latest Publications
- 30 October 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-10
Robotic versus open radical cystectomy: factors influencing approach Selection, predictors of surgical Conversion and their implications for patient outcomes
- 30 October 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-10
Robotic versus open radical cystectomy: factors influencing approach Selection, predictors of surgical Conversion and their implications for patient outcomes
- Open Access
Association of Travel Burden with Definitive Prostate Cancer Treatment: A United States Registry Cohort Study
Purpose: Prostate cancer (PCa) mortality disparities are partly driven by unequal access to care. Transportation barriers may limit access to definitive treatment. We studied how driving travel time affects receipt of definitive PCa treatment. Materials and Methods: We conducted a cohort study of men with non-metastatic PCa (2000 - 2015; follow-up through 2018) across the metropolitan area cancer registries of seven US states. Travel burden was estimated using Google Maps isochrones representing driving time thresholds to reach the hospital appended to geomasked residential addresses. Outcomes were “no treatment, “ “radical surgery,” or “radiotherapy”. Covariate-adjusted multinomial logistic regression with interaction terms assessed modification by sociodemographic factors. Results: The study included 132,939 men, of whom 37.0% received no treatment, 41.0% underwent surgery, and 22.0% received radiotherapy. Longer driving time (≥90 min vs <30 min) was associated with higher radical prostatectomy (aOR: 1.07, 95% CI: 1.03, 1.12), but lower radiotherapy (0.72, 95% CI: 0.69 - 0.76). Subgroup analyses revealed higher surgery associated with longer driving times among those in nSES Q1 (aOR: 1.33, 95% CI: 1.21-1.45) vs Q5 (aOR: 0.94, 95% CI: 0.86-1.04), those in low (aOR: 1.16, 95% CI: 1.09-1.24) vs high (aOR: 1.03, 95% CI: 0.98-1.09) population density areas, and those with regional (aOR: 1.30, 95% CI: 1.14-1.48) vs localized (aOR: 1.05, 95% CI: 1.00 -1.09) disease. Longer driving time was mostly associated with lower odds of radiotherapy across sociodemographic subgroups. Conclusions: Higher travel burden was associated with lower radiotherapy receipt, but greater surgery use in deprived and rural patients, which warrants further investigation.
Open AccessAssociation of Travel Burden with Definitive Prostate Cancer Treatment: A United States Registry Cohort Study
Purpose: Prostate cancer (PCa) mortality disparities are partly driven by unequal access to care. Transportation barriers may limit access to definitive treatment. We studied how driving travel time affects receipt of definitive PCa treatment. Materials and Methods: We conducted a cohort study of men with non-metastatic PCa (2000 - 2015; follow-up through 2018) across the metropolitan area cancer registries of seven US states. Travel burden was estimated using Google Maps isochrones representing driving time thresholds to reach the hospital appended to geomasked residential addresses. Outcomes were “no treatment, “ “radical surgery,” or “radiotherapy”. Covariate-adjusted multinomial logistic regression with interaction terms assessed modification by sociodemographic factors. Results: The study included 132,939 men, of whom 37.0% received no treatment, 41.0% underwent surgery, and 22.0% received radiotherapy. Longer driving time (≥90 min vs <30 min) was associated with higher radical prostatectomy (aOR: 1.07, 95% CI: 1.03, 1.12), but lower radiotherapy (0.72, 95% CI: 0.69 - 0.76). Subgroup analyses revealed higher surgery associated with longer driving times among those in nSES Q1 (aOR: 1.33, 95% CI: 1.21-1.45) vs Q5 (aOR: 0.94, 95% CI: 0.86-1.04), those in low (aOR: 1.16, 95% CI: 1.09-1.24) vs high (aOR: 1.03, 95% CI: 0.98-1.09) population density areas, and those with regional (aOR: 1.30, 95% CI: 1.14-1.48) vs localized (aOR: 1.05, 95% CI: 1.00 -1.09) disease. Longer driving time was mostly associated with lower odds of radiotherapy across sociodemographic subgroups. Conclusions: Higher travel burden was associated with lower radiotherapy receipt, but greater surgery use in deprived and rural patients, which warrants further investigation.
- 9 September 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (4) , 1239-1247
Medicolegal landscape of prostate cancer ablative therapy: a national legal database analysis of malpractice claims (1970–2024)
Background With the advancement of MR-based imaging, prostate cancer ablative therapies have seen increased interest to reduce complications of prostate cancer treatment. Although less invasive, they do carry procedural risks, including rectal injury. To date, the medicolegal aspects of ablative therapy remain underexplored. In this study, we aim to analyze malpractice lawsuits related to prostate cancer ablative therapies using a national legal database. Methods In this retrospective study, we utilized the LexisNexis Database to analyze ablative therapy malpractice lawsuits between 1970 and 2024. We searched for keywords “ablative therapy” “focal therapy” “high-intensity focused ultrasound” “HIFU” “cryotherapy” “cryoablation” “laser” “irreversible electroporation” and “IRE” We excluded cases that did not involve ablative treatment of prostate cancer. We then reviewed cases for treatment method, allegation, claimed liabilities, verdict, and plaintiff award. Results We identified 180 lawsuits using the keywords provided, and 5 cases met inclusion criteria. All five lawsuits involved cryoablation for prostate cancer. The most common precipitating injury was rectal injury (3, 60%). Allegations included negligence (2, 25%), deviation from the standard of care (2, 25%), deliberate indifference (2, 25%), and failure to consent (2, 25%). Verdicts were predominantly favorable to defendants (4, 80%), and one case (20%) resulted in an unknown outcome. Conclusions Ablative therapy had a limited number of lawsuits, with outcomes favorable to surgeons and minimal financial payouts. As ablative therapy continues to gain popularity, urologists must practice proper surgical techniques, conduct thorough informed consent, and exercise excellent patient–provider communication to help minimize the occurrence and impact of litigations involving ablative therapy. These findings may help guide future patient risk counseling and support adjustments in malpractice insurance policies as the use of ablative therapies expands, while also informing physicians and hospital systems considering their adoption or expansion.
- 9 September 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (4) , 1239-1247
Medicolegal landscape of prostate cancer ablative therapy: a national legal database analysis of malpractice claims (1970–2024)
Background With the advancement of MR-based imaging, prostate cancer ablative therapies have seen increased interest to reduce complications of prostate cancer treatment. Although less invasive, they do carry procedural risks, including rectal injury. To date, the medicolegal aspects of ablative therapy remain underexplored. In this study, we aim to analyze malpractice lawsuits related to prostate cancer ablative therapies using a national legal database. Methods In this retrospective study, we utilized the LexisNexis Database to analyze ablative therapy malpractice lawsuits between 1970 and 2024. We searched for keywords “ablative therapy” “focal therapy” “high-intensity focused ultrasound” “HIFU” “cryotherapy” “cryoablation” “laser” “irreversible electroporation” and “IRE” We excluded cases that did not involve ablative treatment of prostate cancer. We then reviewed cases for treatment method, allegation, claimed liabilities, verdict, and plaintiff award. Results We identified 180 lawsuits using the keywords provided, and 5 cases met inclusion criteria. All five lawsuits involved cryoablation for prostate cancer. The most common precipitating injury was rectal injury (3, 60%). Allegations included negligence (2, 25%), deviation from the standard of care (2, 25%), deliberate indifference (2, 25%), and failure to consent (2, 25%). Verdicts were predominantly favorable to defendants (4, 80%), and one case (20%) resulted in an unknown outcome. Conclusions Ablative therapy had a limited number of lawsuits, with outcomes favorable to surgeons and minimal financial payouts. As ablative therapy continues to gain popularity, urologists must practice proper surgical techniques, conduct thorough informed consent, and exercise excellent patient–provider communication to help minimize the occurrence and impact of litigations involving ablative therapy. These findings may help guide future patient risk counseling and support adjustments in malpractice insurance policies as the use of ablative therapies expands, while also informing physicians and hospital systems considering their adoption or expansion.
- 15 April 2025
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 41 (8) , 2108-2116
Prostate Cancer Screening Among Traditionally Underserved Populations at a Large Public Safety-Net Institution
Background Existing literature underscores racial and sociodemographic disparities in prostate cancer screening (PCS) in the USA. Objective To evaluate whether traditional PCS disparities are evident within a health safety-net institution tailored to support traditionally underserved populations. Design A retrospective cohort study using electronic health-record data was conducted at an urban safety-net institution. Participants Male patients aged 51–70 years with a primary care provider (PCP) visit from 2018 to 2019 were included. Main Measures The primary outcome was PCS, defined as receiving a Prostate Specific Antigen (PSA) blood test within the study period. Investigated patient characteristics included self-reported race and ethnicity, language, insurance, marital status, median household income, serious mental illness (SMI), substance use disorder (SUD), and family history of prostate cancer (PCa). Bivariate analyses using chi-squared tests and multivariable logistic regression analyses were performed to compare PCS rates between the groups. Key Results The cohort included 10,059 men, of which 40.4% had PCS. In total, 57.3% of the study population was of non-White race and 61.4% of non-North American/European ethnicity. A total of 31.2% had limited English proficiency (LEP), 17.8% had SMI, and 13.2% had SUD. In multivariable analysis of race, Black patients (OR 1.96, 95%CI 1.71–2.24, p < 0.001) and Hispanic patients (OR 1.51, 95%CI 1.3–1.76, p < 0.001) had significantly higher odds of PCS than White patients. Patients with LEP did not exhibit significantly lower screening rates than English-speaking patients (ORs 0.99–1.17). Conclusions Within a healthcare institution designed and implemented to meet the needs of underserved populations, traditional racial and sociodemographic disparities in PCS are not evident. Graphical Abstract
- 15 April 2025
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 41 (8) , 2108-2116
Prostate Cancer Screening Among Traditionally Underserved Populations at a Large Public Safety-Net Institution
Background Existing literature underscores racial and sociodemographic disparities in prostate cancer screening (PCS) in the USA. Objective To evaluate whether traditional PCS disparities are evident within a health safety-net institution tailored to support traditionally underserved populations. Design A retrospective cohort study using electronic health-record data was conducted at an urban safety-net institution. Participants Male patients aged 51–70 years with a primary care provider (PCP) visit from 2018 to 2019 were included. Main Measures The primary outcome was PCS, defined as receiving a Prostate Specific Antigen (PSA) blood test within the study period. Investigated patient characteristics included self-reported race and ethnicity, language, insurance, marital status, median household income, serious mental illness (SMI), substance use disorder (SUD), and family history of prostate cancer (PCa). Bivariate analyses using chi-squared tests and multivariable logistic regression analyses were performed to compare PCS rates between the groups. Key Results The cohort included 10,059 men, of which 40.4% had PCS. In total, 57.3% of the study population was of non-White race and 61.4% of non-North American/European ethnicity. A total of 31.2% had limited English proficiency (LEP), 17.8% had SMI, and 13.2% had SUD. In multivariable analysis of race, Black patients (OR 1.96, 95%CI 1.71–2.24, p < 0.001) and Hispanic patients (OR 1.51, 95%CI 1.3–1.76, p < 0.001) had significantly higher odds of PCS than White patients. Patients with LEP did not exhibit significantly lower screening rates than English-speaking patients (ORs 0.99–1.17). Conclusions Within a healthcare institution designed and implemented to meet the needs of underserved populations, traditional racial and sociodemographic disparities in PCS are not evident. Graphical Abstract
- 1 November 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-7
Trend of ambulatory benign prostatic obstruction surgeries during COVID-19 pandemic
Introduction Benign prostatic obstruction (BPO) is one of the most common causes of male lower urinary tract symptoms. Some institutions routinely perform BPO surgeries in ambulatory setting, while others elect for overnight hospitalization. With the COVID-19 pandemic limiting resources and hospital space for elective surgery, we investigated the time trend of ambulatory BPO procedures performed around the COVID-19 outbreak. Methods We identified BPO surgeries from the California State Inpatient and State Ambulatory Surgery Databases between 2018 and 2020. Our primary outcome was the proportion of procedures performed in ambulatory settings with a length of stay of zero days. Univariable and multivariable analyses were performed to analyze factors associated with ambulatory surgery around the COVID-19 outbreak. Spline regression with a knot at the pandemic outbreak was performed to compare time trends pre- and post-pandemic. Results Among 37,148 patients who underwent BPO procedures, 30,067 (80.9%) were ambulatory. Before COVID-19, 80.1% BPO procedures were performed ambulatory, which increased to 83.4% after COVID-19 outbreak (p < 0.001). In multivariable model, BPO procedures performed after COVID-19 outbreak were 1.26 times more likely to be ambulatory (OR 1.26, 95% CI 1.14–1.40, p < 0.0001). Spline curve analysis indicated significantly different trend of change pre- and post-pandemic (p = 0.006). Conclusions We observed a rising trend of BPO surgeries performed in ambulatory setting post-pandemic. It remains to be seen if the observed ambulatory transition remains as we continue to recover from the pandemic.
- 1 November 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-7
Trend of ambulatory benign prostatic obstruction surgeries during COVID-19 pandemic
Introduction Benign prostatic obstruction (BPO) is one of the most common causes of male lower urinary tract symptoms. Some institutions routinely perform BPO surgeries in ambulatory setting, while others elect for overnight hospitalization. With the COVID-19 pandemic limiting resources and hospital space for elective surgery, we investigated the time trend of ambulatory BPO procedures performed around the COVID-19 outbreak. Methods We identified BPO surgeries from the California State Inpatient and State Ambulatory Surgery Databases between 2018 and 2020. Our primary outcome was the proportion of procedures performed in ambulatory settings with a length of stay of zero days. Univariable and multivariable analyses were performed to analyze factors associated with ambulatory surgery around the COVID-19 outbreak. Spline regression with a knot at the pandemic outbreak was performed to compare time trends pre- and post-pandemic. Results Among 37,148 patients who underwent BPO procedures, 30,067 (80.9%) were ambulatory. Before COVID-19, 80.1% BPO procedures were performed ambulatory, which increased to 83.4% after COVID-19 outbreak (p < 0.001). In multivariable model, BPO procedures performed after COVID-19 outbreak were 1.26 times more likely to be ambulatory (OR 1.26, 95% CI 1.14–1.40, p < 0.0001). Spline curve analysis indicated significantly different trend of change pre- and post-pandemic (p = 0.006). Conclusions We observed a rising trend of BPO surgeries performed in ambulatory setting post-pandemic. It remains to be seen if the observed ambulatory transition remains as we continue to recover from the pandemic.
- Open Access
Charlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer
Purpose: To test the association between the Charlson–Deyo Comorbidity Index (CCI) and the recurrence of non-muscle-invasive bladder cancer (NMIBC). Methods: NMIBC (Ta, T1, TIS) patients who underwent transurethral resection of bladder tumor (TURB) between 2010 and 2018 were identified within a retrospective data repository of a large university hospital. Kaplan–Meier estimates and uni- and multivariable Cox regression models tested for differences in risk of recurrence according to low vs. high comorbidity burden (CCI ≤ 4 vs. >4) and continuously coded CCI. Results: A total of 1072 NMIBC patients were identified. The median follow-up time of the study population was 55 months (IQR 29.6–79.0). Of all 1072 NMIBC patients, 423 (39%) harbored a low comorbidity burden vs. 649 (61%) with a high comorbidity burden. Overall, the rate of recurrence was 10% at the 12-month follow-up vs. 22% at the 72-month follow-up. In low vs. high comorbidity burden groups, rates of recurrence were 6 vs. 12% at 12 months and 18 vs. 25% at 72 months of follow-up (p = 0.02). After multivariable adjustment, a high comorbidity burden (CCI > 4) independently predicted a higher risk of recurrence (HR 1.42, 95% confidence interval (CI) 1.06–1.92, p = 0.018). After multivariable adjustment, the hazard of recurrence increased by 5% per each one-unit increase on the CCI scale (HR 1.05, 95% CI 1.00–1.10, p = 0.04). Conclusions: Comorbidities in NMIBC patients are common. Our data suggest that patients with higher CCI have an increased risk of BC recurrence. As a consequence, patients with a high comorbidity burden should be particularly encouraged to adhere to NMIBC guidelines and conform to follow-up protocols.
Open AccessCharlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer
Purpose: To test the association between the Charlson–Deyo Comorbidity Index (CCI) and the recurrence of non-muscle-invasive bladder cancer (NMIBC). Methods: NMIBC (Ta, T1, TIS) patients who underwent transurethral resection of bladder tumor (TURB) between 2010 and 2018 were identified within a retrospective data repository of a large university hospital. Kaplan–Meier estimates and uni- and multivariable Cox regression models tested for differences in risk of recurrence according to low vs. high comorbidity burden (CCI ≤ 4 vs. >4) and continuously coded CCI. Results: A total of 1072 NMIBC patients were identified. The median follow-up time of the study population was 55 months (IQR 29.6–79.0). Of all 1072 NMIBC patients, 423 (39%) harbored a low comorbidity burden vs. 649 (61%) with a high comorbidity burden. Overall, the rate of recurrence was 10% at the 12-month follow-up vs. 22% at the 72-month follow-up. In low vs. high comorbidity burden groups, rates of recurrence were 6 vs. 12% at 12 months and 18 vs. 25% at 72 months of follow-up (p = 0.02). After multivariable adjustment, a high comorbidity burden (CCI > 4) independently predicted a higher risk of recurrence (HR 1.42, 95% confidence interval (CI) 1.06–1.92, p = 0.018). After multivariable adjustment, the hazard of recurrence increased by 5% per each one-unit increase on the CCI scale (HR 1.05, 95% CI 1.00–1.10, p = 0.04). Conclusions: Comorbidities in NMIBC patients are common. Our data suggest that patients with higher CCI have an increased risk of BC recurrence. As a consequence, patients with a high comorbidity burden should be particularly encouraged to adhere to NMIBC guidelines and conform to follow-up protocols.